Boost to AEterna Zentaris's filing plans for first-in-class anticancer
This article was originally published in Scrip
The EMA has informed AEterna Zentaris that the ongoing Phase III study of its lead anticancer, perifosine, in advanced colorectal cancer, along with safety data generated in other clinical studies, will be enough to file the drug.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.